▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent Articles by Max Macaluso

Dec 13, 2013 by Max Macaluso and Michael Olsen, CFA

Will Obamacare Crush These Health Care Giants?

The uncertainty surrounding the Affordable Care Act looms large, but will managed care stocks like WellPoint and UnitedHealth continue to outperform the market?

Dec 11, 2013 by Max Macaluso and Simon Erickson

What OncoMed's Deal With Celgene Means for Investors

A look at Celgene's latest deal with OncoMed, a small biotech that went public just a few months ago.

Dec 1, 2013 by Max Macaluso

3 Drugs That Changed Medicine (and Were Discovered by Accident)

Pfizer and Allergan market game-changing drugs that were discovered by accident -- but how did it happen?

Nov 29, 2013 by Max Macaluso

AstraZeneca Stock: 3 Things to Know

What should investors know about drugmaker AstraZeneca (NYSE: AZN) before buying or selling?

Nov 29, 2013 by Max Macaluso

Teva Stock: 3 Key Things to Know

What key issues should investors look at when analyzing Teva's stock?

Nov 27, 2013 by Max Macaluso and David Gardner

Motley Fool Co-Founder David Gardner on Investing for Beginners

One of our head Fools discusses why some people are fearful of managing their own money, and how The Motley Fool is helping.

Nov 26, 2013 by Max Macaluso and Simon Erickson

Novo Nordisk's Biggest Strength and Weakness

Is Novo Nordisk's (NYSE: NVO) diabetes treatment-focused strategy wise, or should the company diversify?

Nov 25, 2013 by Max Macaluso and David Gardner

Kickstarter and the "Long Tail"

Motley Fool co-founder David Gardner's thoughts on revolutionary platform Kickstarter.

Nov 24, 2013 by Max Macaluso and David Gardner

How Investors Can Look Beyond the Numbers

Today’s business leaders lead lives that are public in ways we couldn’t have imagined 25 years ago, making investors’ job just a little easier.

Nov 19, 2013 by Max Macaluso

"Invest in What You Know"? Maybe, Maybe Not.

David Gardner offers his thoughts on how to get your feet wet when investing in an unfamiliar industry.

Nov 19, 2013 by Max Macaluso

Should You Fear Stocks in the Health-Care Space?

Motley Fool co-founder David Gardner discusses health-care stocks and two options for investors who fear them.

Nov 14, 2013 by Max Macaluso and David Gardner

Motley Fool Co-Founder David Gardner's Approach to "Fearless" Investing

Motley Fool Co-Founder and Chief Rule Breaker David Gardner discusses his brand of "fearless" investing, how to look at stocks in the biotech industry, his investing philosophy -- and yes, even Kickstarter and the Pebble smartwatch.

Oct 30, 2013 by Max Macaluso and Alison Southwick

Down 13%: More Bad Luck for Amarin Corporation plc

Shares of Amarin, which have already been crushed this month, dropped another 13% today. What was behind the plunge?

Oct 30, 2013 by Max Macaluso and Alison Southwick

Down 8%: What's Behind Teva's Massive Plunge?

Teva Pharmaceuticals is down 8% today, but it's not directly due to competition in the multiple sclerosis space from new drugs like Biogen's Tecfidera. To find out what happened and what may lie ahead for Teva, watch this video.

Oct 28, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Another Big Win for Big Biotech Biogen?

Biogen reported its third-quarter results, but was it all good news for the big biotech company?

Oct 28, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Why This Dow Heavyweight Sank on Earnings

Why did shares of Dow component Merck drop as other drugmakers, such as Bristol-Myers Squibb and AstraZeneca, rose today?

Oct 18, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

What Was Behind Ariad's 40% Drop?

Ariad Pharmaceuticals has already dropped significantly this week --- what was behind today's move?

Oct 18, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

What Was Behind Anacor's 28% Climb?

Why did shares of biotech company Anacor surge today?

Oct 18, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

The Next Cholesterol-Fighting Blockbuster Drug?

Regeneron and its partner Sanofi reported results from a late-stage trial for their new cholesterol-lowering drug. Can this be the next Lipitor?

Oct 16, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Abbott's Earnings Made Easy

What were the takeaways from Abbott's third-quarter results?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services